The aim of our study is to give a survey of the most efficient methods for treatment and prevention of non-steroidal anti-inflammatory
drug (
NSAID)-induced gastrointestinal adverse in cases when antiphlogistic treatment cannot be discontinued due to active and progressive
joint disease. Analysis of published studies shows that, the
proton pump inhibitors (
omeprazole) are the most efficient agents in treatment of gastric and
duodenal ulcers induced by
NSAIDs. The analysis shows a reliable effect of
prostaglandin analogues (
misoprostol) as well.
Prostaglandin analogues (
misoprostol) proved the most effective in treatment of gastric erosions. Prophylaxis of adverse gastrointestinal mucosal abnormalities can be primary or secondary.
Secondary prevention is intended for patients with gastrointestinal symptoms or those treated for mucosal defects (
ulcer, erosions). The standard prevention using H2-antagonists or sucralphate does not provide sufficient protection against
NSAID in these patients, but
omeprazole reduces the chance of a peptic lesion relapse. Primary prevention is intended for patients with a higher risk of gastrointestinal complications (age above 60, history of
peptic ulcer, a higher dose of
NSAID, simultaneous treatment with
glucocorticoids or
anticoagulants).
Diclofenac with
misoprostol and
nabumetone reduce the incidence of
gastroduodenal ulcers and their complications in short-term as well long-term studies.
Meloxicam reduces the incidence of gastroduodenal mucosal abnormalities is short-term studies.
Nimesulide is associated with a lower incidence of adverse gastrointestinal events, but the fact is that, reliable data on
gastroduodenal ulcer incidence reduction or their complications are not available.